Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680544 | 0.85 | PTGS2 (0.48) | MAPK14CSNK1DMAPK9MAPK10PTGS2 | |
| SCHEMBL4680761 | 0.80 | PTGS2 (0.53) | MAPK14CSNK1DMAPK9MAPK10PTGS2 | |
| SCHEMBL4334618 | 0.78 | MAPK14 (0.66) | MAPK14CSNK1DMAPK9MAPK10PTGS2 | |
| SCHEMBL4677679 | 0.78 | MAPK14 (0.60) | MAPK14CSNK1DMAPK9 | |
| SCHEMBL2473230 | 0.73 | PTGS2 (0.40) | MAPK14CSNK1DMAPK9MAPK10PTGS2 | |
| SCHEMBL4680533 | 0.73 | PTGS2 (0.49) | MAPK14CSNK1DMAPK10PTGS2PTGS1 | |
| SCHEMBL11099601 | 0.70 | PTGS2 (0.73) | PTGS2PTGS1PDE3A | |
| SCHEMBL4333425 | 0.70 | MAPK14 (0.61) | MAPK14CSNK1DMAPK9MAPK10MAPK11 | |
| SCHEMBL14591605 | 0.70 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL2471415 | 0.68 | LMNA (0.53) | PTGS2PTGS1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218369-B1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1218369-A4 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTX PHARMACEUTICALS INCORPORATED | 2003-08-07 | — | — | US | disclosed |
| EP-1218369-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012621-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | MAPK1, PACSIN2, MAP3K1 | MAPK14 48/4885CSNK1D 62/4885MAPK9 65/4885 |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | MAPK14 43/4885CSNK1D 78/4885MAPK9 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.